AMAffaf Mahmood

Affaf Mahmood

*This is an algorithmically generated author record based on publicly available information.

Affaf Mahmood has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Indobufen Versus Aspirin in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis

    by Ahmad Hassan, Muhammad Rayyan Yousafi, Muhammad Essa, Affaf Mahmood, Ahmed Asif, Muhammad Sarmad, Usama Ahmad, Amna Iman, Semil Saleem, Kanza Raees, et al.

    Background: Acute ischemic stroke (AIS) is a major cause of death and disability worldwide. Early antiplatelet therapy reduces recurrence and improves outcomes. Although aspirin is standard treatment, its use is limited by bleeding risk. Indobufen, a reversible cyclooxygenase inhibitor with shorter platelet inhibition, may offer a safer alternative. Objective: To compare the efficacy and safety of indobufen versus aspirin in patients with AIS. Methods: A systematic review and meta-analysis was performed according to PRISMA guidelines. PubMed, Embase, Cochrane Library, and ScienceDirect were searched through February 2026 for randomized controlled trials comparing indobufen with aspirin in adults with AIS. Primary outcomes were functional outcomes (modified Rankin Scale), neurological improvement (NIHSS) at 90 days, recurrent ischemic stroke at 90 days, and composite vascular events. Secondary outcomes included bleeding and other adverse events. Pooled estimates were calculated using fixed- or random-effects models based on heterogeneity. The risk of bias was assessed using Cochrane RoB 2.0. Results: Four randomized controlled trials (278 records screened) were included. Indobufen showed no significant difference versus aspirin in NIHSS improvement at 90 days (MD: 0.01, 95% CI: −0.07 to 0.09) or recurrent ischemic stroke (OR: 0.54, 95% CI: 0.05-5.61). However, indobufen significantly improved modified Rankin Scale outcomes (MD: −1.11, 95% CI: −1.32 to −0.90) and reduced moderate-to-severe bleeding at 3 months (OR: 0.57, 95% CI: 0.35-0.92). Conclusions: Indobufen provides efficacy comparable to aspirin, with better functional outcomes and lower short-term bleeding risk, supporting its potential as an alternative antiplatelet therapy in AIS. Larger, international, multicenter trials are warranted. Larger, high-quality, multicenter international trials are warranted to confirm these findings.

  • Open Access

    Perioperative dexmedetomidine for the prevention of postoperative delirium in elderly patients undergoing orthopedic surgery: a systematic review and meta-analysis of randomized controlled trials

    by Syed Faqeer Hussain Bokhari, Affaf Mahmood, Saira Shamim, Khansa Mehmood, Rabia Amjad, Abdul Saboor Khan, Aiman Jeet Kaur, Ibrahim Salau, Fnu Maryam, Ahmad Hassan, et al.

    Background: Postoperative delirium (POD) is a frequent and morbid complication in elderly patients undergoing orthopedic surgery. Although dexmedetomidine has been studied for delirium prevention in mixed surgical populations, evidence specific to orthopedic procedures and perioperative administration strategies remains fragmented. Objective: To evaluate the efficacy and cardiovascular safety of perioperative dexmedetomidine for POD prevention in elderly patients undergoing orthopedic surgery and to examine its impact on recovery outcomes. Methods: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials (RCTs) comparing perioperative dexmedetomidine with placebo or standard care in adults undergoing orthopedic surgery was conducted. The primary outcome was POD incidence. Secondary outcomes included time-specific delirium, perioperative cardiovascular adverse events, length of hospital stay, in-hospital complications, and mortality. Results: Seven RCTs, including 2060 patients, were analyzed. Dexmedetomidine significantly reduced overall POD incidence [odds ratio (OR) = 0.42; 95% CI 0.32–0.54; I 2 = 0%; P < 0.00001]. Time-specific reductions were observed at 24 h (OR = 0.36; 95% CI 0.22–0.57; P < 0.0001) and 72 h (OR = 0.46; 95% CI 0.24–0.87; P = 0.02), but not at 48 h (OR = 0.38; 95% CI 0.12–1.15; P = 0.09). Intraoperative cardiovascular adverse events were increased overall (OR = 1.65; 95% CI 1.10–2.47; P = 0.02), while individual events were not significantly different. Postoperatively, hypertension was reduced (OR = 0.52; 95% CI 0.30–0.91; P = 0.02). Hospital stay was significantly shorter (mean difference = −1.31 days; 95% CI −1.93 to −0.69; P < 0.0001), with no significant differences in in-hospital complications (OR = 0.74; P = 0.06) or mortality (OR = 0.89; P = 0.83). Conclusion: Perioperative dexmedetomidine reduces POD and improves recovery in elderly orthopedic patients, with manageable cardiovascular effects under monitoring. Further large-scale trials are needed to determine optimal dosing, timing, and long-term neurocognitive outcomes.

  • Minimally Invasive vs. Open Pancreaticoduodenectomy for Distal Cholangiocarcinoma: A Systematic Review and Meta-analysis

    by Danyal Bakht, Azmir Ali Khan, Hafsa Hashmi, Maaz Amir, Ubaid Ur Rehman, Affaf Mahmood, Mehrab Naeem, Muhammad Ahmad Raza, Fatima Naeem, Arbab Sarfraz, et al.

    Background Distal cholangiocarcinoma (dCCA) is a rare but aggressive biliary malignancy arising from the distal bile duct with significant clinical burden. Pancreaticoduodenectomy (minimally invasive or open) remains the only potentially curative treatment for dCCA. However, the comparative safety and oncologic adequacy of minimally invasive versus open pancreaticoduodenectomy remains unclear, creating an evidence gap that this systematic review addresses. Objective This systematic review and meta-analysis aimed to compare perioperative outcomes and oncologic effectiveness of MIPD versus OPD in patients undergoing surgery for distal cholangiocarcinoma. Methods A systematic literature search of PubMed, Embase, Cochrane Library, and Science Direct was conducted through April 2025 in accordance with PRISMA guidelines. Eligible studies included cohort studies, randomized controlled trials, and case-control studies comparing MIPD (laparoscopic or robotic) with OPD in dCCA. Data regarding operative parameters, oncologic outcomes, perioperative morbidity, and mortality were extracted. Meta-analysis was performed using Review Manager 5.4, applying fixed- or random-effects models based on heterogeneity. Results Seven retrospective cohort studies comprising 1,803 patients (775 MIPD vs. 1,028 OPD) were included. MIPD was associated with significantly lower blood loss (WMD − 100.86 mL, 95% CI − 107.27 to − 94.46; I² = 90%; p < 0.001) and shorter hospital stay (WMD − 2.46 days, 95% CI − 4.08 to − 0.84; I² = 89%; p = 0.003), but longer operative time (WMD 52.60 min, 95% CI 16.82 to 88.39; I² = 99%; p = 0.004). There was no significant difference in major complications (Clavien-Dindo ≥ III) (OR 0.97, 95% CI 0.74–1.28; p = 0.85) or postoperative mortality (OR 0.46, 95% CI 0.16–1.33; I² = 56%; p = 0.15) between groups. Importantly, long-term oncologic outcomes were also comparable between groups, with no significant differences observed in overall survival (HR 0.90, 95% CI 0.77–1.05; p = 0.19) or disease-free survival (HR 0.98, 95% CI 0.83–1.16; p = 0.83). No survival disadvantage was demonstrated for MIPD compared with OPD. Conclusion MIPD appears to be a safe and feasible alternative to OPD for selected patients with distal cholangiocarcinoma, offering perioperative benefits without compromising oncologic outcomes. Importantly, available evidence also demonstrates no compromise in long-term oncologic outcomes, with comparable overall and disease-free survival between MIPD and OPD. However, given the rarity of dCCA, stand-alone randomized controlled trials are unlikely to be feasible. Future evidence should therefore focus on stratifying dCCA patients within ongoing or future multicenter trials of minimally invasive pancreaticoduodenectomy for periampullary malignancies, as well as prospective international registry-based studies with mandatory reporting of histological subtypes to generate high-quality, generalizable evidence.


  • Open Access

    Shifting burdens: heart failure and pneumonia mortality patterns in the United States, 1999–2020

    by Affaf Mahmood, Farah Latif, Sana Latif, Mohit Kumar, Soojal Srichand, Sumet Kumar, Neeraj Kumar, Kuldeep Dalpat Rai, Aneesh Kumar Sangtiani, Laksh Kumar, et al.

    Heart failure (HF) and pneumonia are leading causes of mortality in the United States, yet limited research has examined deaths attributable to their co-occurrence. Understanding demographic and geographic disparities in these mortality trends is critical for guiding public health interventions. Using data from the CDC Wide-ranging Online Data for Epidemiologic Research database, this study analyzed mortality from 1999 to 2020 among individuals aged 25 years and older. Age-adjusted mortality rates (AAMRs) per 100 000 population were calculated by sex, race/ethnicity, region, and rural–urban classification, with temporal trends assessed via Joinpoint regression. A total of 542 805 deaths were attributed to HF and pneumonia. Mortality declined steadily from 1999 through 2019 but rose sharply thereafter. The overall AAMR was 11.4, consistently higher in men than in women. Racial and ethnic disparities were evident: White individuals had the highest AAMR (11.6), followed by Black (10.2), American Indian/Alaska Native (9.6), and Asian/Pacific Islander populations (6.5). Regionally, the Midwest had the highest rate (12.3), and rural areas (15.3) exceeded urban areas (10.5). State-level mortality was greatest in West Virginia, Kentucky, and Oklahoma. These findings highlight a reversal of declining trends and underscore persistent disparities, emphasizing the need for targeted prevention, improved healthcare access, and community-based interventions.

  • Top Cited Papers
    Open Access

    Heart failure and tobacco use disorder: mortality trends and disparities in the United States

    by Affaf Mahmood, Farah Latif, Sana Latif, David N. Smith, Biruk D. Ayalew, Adarsh Raja, Sumet Kumar, Neeraj Kumar, Kuldeep D. Rai, Aneesh K. Sangtiani, et al.

    Introduction: Tobacco use disorder is associated with increased morbidity and mortality from heart failure (HF) in the United States. Despite this burden, long-term trends in HF mortality among tobacco users and the extent of demographic and geographic disparities remain poorly understood, limiting targeted prevention and intervention strategies. This study examines these trends and disparities using the CDC WONDER database. Methods: Mortality data from 2003 to 2020 were analyzed for individuals aged ≥25 years with tobacco use disorder who died from HF. Age-adjusted mortality rates (AAMRs) per 100 000 general population were calculated. Joinpoint regression estimated annual percentage changes. Subgroup analyses were conducted by sex, race/ethnicity, region, and rural–urban classification. Results: From 2003 to 2020, 576 781 HF deaths occurred among tobacco users aged ≥25 years. The overall AAMR nearly quadrupled during this period. Men consistently exhibited higher AAMRs than women. Among racial/ethnic groups, American Indians or Alaska Natives had the highest rates, followed by Whites, Blacks, and Asian or Pacific Islanders. Regionally, the Midwest recorded the highest mortality, followed by the South, Northeast, and West. Rural populations had higher AAMRs than urban populations. At the state level, Oregon showed the highest AAMR, while California had the lowest. Conclusion: The sharp rise in HF mortality among tobacco users underscores critical public health gaps. Disparities were most pronounced among men, American Indians or Alaska Natives, Midwestern residents, and rural populations. By identifying high-risk populations and regions, this study provides actionable insights to guide targeted interventions, tobacco cessation programs, and equitable healthcare access, helping to address the growing burden of HF in tobacco users.